Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high-risk squamous cell head and neck cancer

被引:31
作者
Suwinski, Rafal [1 ]
Bankowska-Wozniak, Magdalena [2 ]
Majewski, Wojciech [1 ]
Idasiak, Adam [1 ]
Maciejewski, Adam [1 ]
Ziolkowska, Ewa [2 ]
Windorbska, Wieslawa [2 ]
Skladowski, Krzysztof [1 ]
Miszczyk, Leszek [1 ]
Maciejewski, Boguslaw [1 ]
机构
[1] Inst Oncol, M Sklodowska Curie Mem Canc Ctr, Dept Radiat Oncol, Gliwice, Poland
[2] Reg Ctr Oncol, Bydgoszcz, Poland
关键词
randomized clinical trial; head and neck cancer; accelerated radiotherapy; combined treatment;
D O I
10.1016/j.radonc.2008.02.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the normal tissue reactions and loco-regional control rates (LRC) in patients treated with 7-days-a-week postoperative continuous irradiation (p-CAIR) compared to conventionally fractionated 5-days-a-week postoperative radiotherapy (CF). Materials/methods: Between 2001 and 2004, 279 patients with high-risk squamous cell cancer of the larynx (158 pts.) or cancer of the oral cavity/oropharynx (121 pts.) were enrolled. They were stratified according to the primary cancer site (larynx vs. others) and the treating center and randomized to receive 63 Gy in fractions of 1.8 Gy given 5-days-a-week (140 pts: CF) or 7-days-a-week (139 pts: p-CAIR). Results: The acute and late toxicity was considered acceptable, although the proportion of patients with confluent mucositis was higher in p-CAIR compared to CF (60.0 vs. 33.3%). The actuarial 3-year LRC were 64 vs. 70% for CF and p-CAIR, respectively, p = 0.32. A statistically significant improvement in 3-year LRC in p-CAIR arm appeared in a subset of the patients with cancer of the oropharynx/oral cavity (74% p-CAIR vs. 53% CF, p = 0.02). By contrast, there was no improvement in LRC in a subset of the patients with cancer of the larynx (p = 0.46). Conclusion: An improvement in LRC attributable to acceleration of postoperative radiotherapy appeared restricted to the patients with cancer of the oropharynx/oral cavity. In patients with cancer of the larynx acceleration of postoperative radiotherapy did not have any beneficial effect. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:155 / 163
页数:9
相关论文
共 18 条
[1]   Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer [J].
Ang, KK ;
Trotti, A ;
Brown, BW ;
Garden, AS ;
Foote, RL ;
Morrison, WH ;
Geara, FB ;
Klotch, DW ;
Goepfert, H ;
Peters, LJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (03) :571-578
[2]   ACCELERATED VERSUS CONVENTIONAL FRACTIONATION IN THE POSTOPERATIVE IRRADIATION OF LOCALLY ADVANCED HEAD AND NECK-CANCER - INFLUENCE OF TUMOR PROLIFERATION [J].
AWWAD, HK ;
KHAFAGY, Y ;
BARSOUM, M ;
EZZAT, S ;
ELATTAR, I ;
FARAG, H ;
AKOUSH, H ;
MEABID, H ;
ZAGHLOUL, MS .
RADIOTHERAPY AND ONCOLOGY, 1992, 25 (04) :261-266
[3]   Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation [J].
Awwad, HK ;
Lotayef, M ;
Shouman, T ;
Begg, AC ;
Wilson, G ;
Bentzen, SM ;
Abd El-Moneim, H ;
Eissa, S .
BRITISH JOURNAL OF CANCER, 2002, 86 (04) :517-523
[4]   Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial [J].
Bentzen, SA ;
Saunders, MI ;
Dische, S ;
Bond, SJ .
RADIOTHERAPY AND ONCOLOGY, 2001, 60 (02) :123-135
[5]   Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial [J].
Bentzen, SM ;
Atasoy, BM ;
Daley, FM ;
Dische, S ;
Richman, PI ;
Saunders, MI ;
Trott, KR ;
Wilson, GD .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5560-5567
[6]   Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer [J].
Bernier, J ;
Domenge, C ;
Ozsahin, M ;
Matuszewska, K ;
Lefèbvre, JL ;
Greiner, RH ;
Giralt, J ;
Maingon, P ;
Rolland, F ;
Bolla, M ;
Cognetti, F ;
Bourhis, J ;
Kirkpatrick, A ;
van Glabbeke, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) :1945-1952
[7]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[8]   Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck [J].
Cooper, JS ;
Pajak, TF ;
Forastiere, AA ;
Jacobs, J ;
Campbell, BH ;
Saxman, SB ;
Kish, JA ;
Kim, HE ;
Cmelak, AJ ;
Rotman, M ;
Machtay, M ;
Ensley, JF ;
Chao, KSC ;
Schultz, CJ ;
Lee, N ;
Fu, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) :1937-1944
[9]  
Cooper JS, 1998, HEAD NECK-J SCI SPEC, V20, P588, DOI 10.1002/(SICI)1097-0347(199810)20:7<588::AID-HED2>3.3.CO
[10]  
2-6